Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Shares of Inari Medical catapulted to a 12-month high Monday on a report medical devices maker Stryker is in advanced talks ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Stryker said its planned acquisition of Inari Medical would strengthen its position in the peripheral vascular market.

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Stryker said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that values the deal at ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Stryker announced a definitive agreement to acquire Inari Medical, Inc. for approximately $4.9 billion. Inari was founded in 201 ...